Stayble Therapeutics appoints new CFO

Stayble Therapeutics AB announces that Erik Kullgren has been appointed as the new CFO, effective August 1, 2024.

Erik Kullgren has an MBA from the School of Economics at the University of Gothenburg and has extensive experience as a CFO for both listed and unlisted companies. He has also been CEO of Reguity Group AB and Dunross & Co AB. Erik Kullgren currently runs his own consulting company where he acts as CFO for, among others, Alzinova AB and Shortcut Media Group.

We welcome Erik as the new CFO of Stayble and look forward to working together. With his solid experience and relevant expertise in our industry and the listed environment, he will be valuable to the company. At the same time, I would like to thank Thomas Pålsson for the fantastic collaboration we have had in recent years, says Andreas Gerward, CEO, Stayble.

For more information

Andreas Gerward, CEO of Stayble Therapeutics AB

Mail: andreas.gerward@stayble.se

Phone: +46 730 808 397

About Stayble Therapeutics AB

Stayble is a clinical pharmaceutical company developing the injection treatment STA363 for chronic disc herniation (LDH). Stayble's vision is to offer patients a simple and effective treatment that targets the underlying cause of the patient's chronic pain and provides lasting pain relief and increased physical function. The treatment is aimed at patients who are not helped by physical therapy and painkillers and is a single injection that is expected to last a lifetime and requires minimal rehabilitation. After convincing data from previous pre-clinical and clinical studies (phase 1b and 2b) in degenerative disc disease, which show a volume reduction of the discs, the Company is currently conducting a phase 1b study for the treatment of herniated discs.

The company's Certified Adviser is Svensk Kapitalmarknadsgranskning AB.